胡亮 研究员

发布者:中西医发布时间:2021-09-07浏览次数:336

胡亮

研究员

Liang Hu

           Associate research fellow



胡亮,研究员 (Liang Hu, Associate research fellow)

电子邮箱(Email):huliang313394234@aliyun.com

办公室电话(TEL):(021) 5132-2266

通讯地址(contact address):浦东新区蔡伦路1200号创新科技楼4B407

(B407, 4/F, Innovation and Technology Building, 1200 Cailun Rd, Pudong, Shanghai)


学习和研究经历

  • 2021.07-至今,  副研究员,上海中医药大学,中西医结合研究院

  • 2017.11-2021.6,副研究员,郑州大学第一附属医院,心血管内科

  • 2011.09-2017.10,助理研究员,中科院上海药物研究所,心血管药理

  • 2013.09-2017.06,博士研究生,复旦大学,生物化学与分子生物学

  • 2008.09-2011.06,硕士研究生,复旦大学,生物化学与分子生物学


研究领域(Research area

  • 血小板异常活化和心肌梗死发病机制

    Mechanisms of platelet hyperactivation in myocardial infarction

  • 传统中药抗血小板在心血管疾病中的治疗机制

    Antiplatelet therapy of traditional chinese medicine in cardiovascular diseases

  • 抗血小板药物筛选和药效学研究

    Antiplatelet agent evaluation and Pharmacological study


研究成果及获奖(Achievements and Awards

专利 (patent)

  • 一种Galectin-3抑制剂的用途及药物组合物(an novel antiplatelet agent targeting Galectin-3)

    专利申请号:202111666381.3

  • 代表血小板反应性的生物标记物在制备心血管药物中的应用(a biomarker predicting cardiovascular diseases)

    专利申请号:202111672184.2

  • 一种双功能抗小板聚集药物及其用途 (an novel antiplatelet agent targeting P2Y12 and PDE1)

    专利号(patent No.)201110034492.2

  • 预测II型糖尿病患者心血管疾病并发症风险的生物标记物 (a biomarker predicting cardiovascular diseases in type II diabetes)

    申请号 (application No.) 201510975407.5


基金支持及参与(Grant Funding

  • 瞬时电位受体TRPM8在血小板中的表达和功能(立项编号:81803522);国家自然科学青年基金;起止日期 :2019年1月 - 2021年12月;主持人

  • 半乳糖凝集素3高表达激活Dectin-1在急性心肌梗死血小板活化中的作用及机制研究 (批准编号:81970305);国家自然科学面上基金;起止日期 :2020年1月 - 2023年12月;主持人


Grant Funding

  • 2018 National Natural Science Foundation of China for Young Scientist

  • 2019 National Natural Science Foundation of China (general program)


论文发表(Publication

  • Chen Y*, Fu W*, Zheng Y, Yang J, Liu Y, Qi Z, Wu M, Fan Z, Yin K, Chen Y, Gao W, Ding Z, Dong J, Li Q#, Zhang S#Hu L#. Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study. Eur Heart J. 2022 Feb 15:ehac034. doi: 10.1093/eurheartj/ehac034. Epub ahead of print. PMID: 35165707. (IF29.9)

  • Zhang S*#, Liu Y*, Wang X*, Yang L*, Li H, Wang Y, Liu M, Zhao X, Xie Y, Yang Y, Zhang S, Fan Z, Dong J, Yuan Z, Ding Z, Zhang Y#Hu L#. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020 Sep 4;13(1):120. doi: 10.1186/s13045-020-00954-7. PMID: 32887634; PMCID: PMC7471641. (IF17.4,高被引,ESI引用前1%)

  • Zhou Y*, Hu L*, Tang W*, Li D, Ma L, Liu H, Zhang S, Zhang X, Dong L, Shen X, Chen S, Xue R, Zhang S. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. J Hematol Oncol. 2021 Jan 7;14(1):9. doi: 10.1186/s13045-020-01028-4. PMID: 33413510; PMCID: PMC7791875. (IF17.4)

  • Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D, Yao Z, Chang L, Pan G, Zhong H, Luo X, Yao K, Sun A, Qian J, Ding Z and Ge J. PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36. Circulation. 2020. IF29.5

  • Chen Y*, Zhang H*, Hu L*, Shi H, Liu X, Jia J, Sun S, Ou Y, Luo X, Zhou G, Shen W#. Pravastatin attenuates atherosclerosis after myocardial infarction by inhibiting inflammatory Ly6C high monocytosis in apolipoprotein E knockout mice, J Int Med Res. 2020 (IF: 1.3)

  • 陈羽斐,胡亮,张红旗,贾剑国,施海明,罗心平,周国民,范维琥,沈伟;麝香保心丸对ApoE-/-小鼠心肌梗死后动脉粥样硬化进程和循环单核细胞亚群的影响,中国中西医结合杂志;2020

  • Hu L, Chang L, Zhang Y, Zhai L, Zhang S, Qi Z, Yan H, Yan Y, Luo X, Zhang S, Wang Y, Kunapuli SP, Ye H, Ding Z#. Platelets express activated p2y12 receptor in patients with diabetes. Circulation. 2017 (IF: 29.5)

  • Zhang S, Zhang SH, Hu L, Zhai L, Xue R, Ye J, Chen L, Mruk J, Cheng G, Kunapuli SP, Ding Z#. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis. Circulation 2015; 131(13): 1160 - 1170 (Featured work with an editorialIF: 29.5)

  • Hu L, Fan Z, Du H, Ni R, Zhang S, Yin K, Ye J, Zhang Y, Wei X, Zhang X, Gross PL, Kunapuli SP, Ding Z#. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106(6): 1204 - 1214 (IF: 5.4)